Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385304> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4308385304 abstract "<h3>Background</h3> Subgroup analysis of EMPOWER-Lung 1, a 1:1 randomized, open-label Phase 3 study, showed improvements in overall survival (OS) and progression-free survival with cemiplimab monotherapy (CEMI, n=283) versus platinum-doublet chemotherapy (CHEMO, n=280) in patients with an ECOG performance status (PS) score 0 and 1 (OS: PS 0: hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.41, 1.44; PS 1: HR 0.54, 95% CI 0.38, 0.76) in patients with aNSCLC with programmed cell death-ligand 1 ≥50%.<sup>1</sup> Post-hoc analyses evaluated patient-reported outcomes (PROs) in both ECOG PS subgroups. <h3>Methods</h3> PROs were assessed at baseline and Day 1 of each treatment cycle for the first 6 cycles, and then on Day 1 of every third cycle using the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 (QLQ-C30) and Lung Cancer Module (QLQ-LC13) questionnaires. Higher scores indicate better functioning and global health status (GHS)/quality of life (QoL), or worse symptom severity. Mixed-model repeated-measures analyses were performed to compare overall change from baseline scores between the two treatment arms while controlling for baseline characteristics. Time to definitive clinically meaningful deterioration (TTD) per 10-point threshold was analyzed using a stratified log-rank test and proportional hazards model.<sup>2</sup> <h3>Results</h3> Baseline PRO scores were broadly similar between treatment arms. Statistically significant difference in overall change from baseline in GHS/QoL favoring CEMI versus CHEMO occurred in the ECOG PS score 1 subgroup (mean treatment difference 5.03, 95% CI 1.90, 8.15, <i>P</i>=0.0017). CEMI also resulted in statistically significant favorable differences in both ECOG subgroups in overall change from baseline in physical and social functioning; fatigue, nausea/vomiting, and constipation symptoms per QLQ-C30; and peripheral neuropathy and alopecia symptoms per QLQ-LC13. There was a statistically significant delay in TTD in physical functioning in the ECOG PS score 1 subgroup, favoring CEMI (HR 0.59, 95% CI 0.37, 0.95, <i>P</i>=0.028). Statistically significant delays in TTD favoring CEMI occurred in both ECOG subgroups in social functioning, fatigue and nausea/vomiting symptoms per QLQ-C30; peripheral neuropathy and alopecia symptoms per QLQ-LC13. When comparing between arms, no analyses yielded statistically significant PRO results favoring CHEMO for any QLQ-C30 or QLQ-LC13 scale. <h3>Conclusions</h3> In this post-hoc analysis of patients with aNSCLC across both ECOG PS subgroups, CEMI resulted in significant overall improvement and delayed TTD relative to CHEMO in multiple patient-reported cancer-related and lung cancer–specific functions and symptoms. Positive PRO results further support the favorable benefit-risk profile of CEMI versus CHEMO in aNSCLC in both PS subgroups. <h3>Acknowledgements</h3> This study was funded by Regeneron Pharmaceuticals, Inc. Medical writing support and typesetting were provided by John G Facciponte, PhD, of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi. <h3>Trial Registration</h3> NCT03088540 <h3>References</h3> Sezer A, Kilickap S, Gümüş M, <i>et al. Lancet</i>. 2021;<b>397</b>(10274):592–604. Sezer A, Gümüş M, Bondarenko I, <i>et al</i>. Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1. Poster P1.15-13. To be presented at the International Association for the Study of Lung Cancer (IASLC), August 6–9, 2022, Vienna, Austria. <h3>Ethics Approval</h3> The protocol and all amendments were approved by the appropriate institutional review board or independent ethics committee at each participating study site. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. <h3>Consent</h3> Written informed consent was obtained for publication of this abstract." @default.
- W4308385304 created "2022-11-11" @default.
- W4308385304 creator A5019547742 @default.
- W4308385304 creator A5023874099 @default.
- W4308385304 creator A5029804493 @default.
- W4308385304 creator A5033323622 @default.
- W4308385304 creator A5040286984 @default.
- W4308385304 creator A5049440330 @default.
- W4308385304 creator A5084515472 @default.
- W4308385304 creator A5085227244 @default.
- W4308385304 creator A5085689787 @default.
- W4308385304 creator A5087603840 @default.
- W4308385304 date "2022-11-01" @default.
- W4308385304 modified "2023-10-16" @default.
- W4308385304 title "582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1" @default.
- W4308385304 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0582" @default.
- W4308385304 hasPublicationYear "2022" @default.
- W4308385304 type Work @default.
- W4308385304 citedByCount "0" @default.
- W4308385304 crossrefType "proceedings-article" @default.
- W4308385304 hasAuthorship W4308385304A5019547742 @default.
- W4308385304 hasAuthorship W4308385304A5023874099 @default.
- W4308385304 hasAuthorship W4308385304A5029804493 @default.
- W4308385304 hasAuthorship W4308385304A5033323622 @default.
- W4308385304 hasAuthorship W4308385304A5040286984 @default.
- W4308385304 hasAuthorship W4308385304A5049440330 @default.
- W4308385304 hasAuthorship W4308385304A5084515472 @default.
- W4308385304 hasAuthorship W4308385304A5085227244 @default.
- W4308385304 hasAuthorship W4308385304A5085689787 @default.
- W4308385304 hasAuthorship W4308385304A5087603840 @default.
- W4308385304 hasBestOaLocation W43083853041 @default.
- W4308385304 hasConcept C126322002 @default.
- W4308385304 hasConcept C143998085 @default.
- W4308385304 hasConcept C159110408 @default.
- W4308385304 hasConcept C168563851 @default.
- W4308385304 hasConcept C203092338 @default.
- W4308385304 hasConcept C207103383 @default.
- W4308385304 hasConcept C2776256026 @default.
- W4308385304 hasConcept C2776694085 @default.
- W4308385304 hasConcept C2776907518 @default.
- W4308385304 hasConcept C2779951463 @default.
- W4308385304 hasConcept C2780739268 @default.
- W4308385304 hasConcept C44249647 @default.
- W4308385304 hasConcept C71924100 @default.
- W4308385304 hasConceptScore W4308385304C126322002 @default.
- W4308385304 hasConceptScore W4308385304C143998085 @default.
- W4308385304 hasConceptScore W4308385304C159110408 @default.
- W4308385304 hasConceptScore W4308385304C168563851 @default.
- W4308385304 hasConceptScore W4308385304C203092338 @default.
- W4308385304 hasConceptScore W4308385304C207103383 @default.
- W4308385304 hasConceptScore W4308385304C2776256026 @default.
- W4308385304 hasConceptScore W4308385304C2776694085 @default.
- W4308385304 hasConceptScore W4308385304C2776907518 @default.
- W4308385304 hasConceptScore W4308385304C2779951463 @default.
- W4308385304 hasConceptScore W4308385304C2780739268 @default.
- W4308385304 hasConceptScore W4308385304C44249647 @default.
- W4308385304 hasConceptScore W4308385304C71924100 @default.
- W4308385304 hasLocation W43083853041 @default.
- W4308385304 hasOpenAccess W4308385304 @default.
- W4308385304 hasPrimaryLocation W43083853041 @default.
- W4308385304 hasRelatedWork W2018515503 @default.
- W4308385304 hasRelatedWork W2024826853 @default.
- W4308385304 hasRelatedWork W2077295477 @default.
- W4308385304 hasRelatedWork W2508640481 @default.
- W4308385304 hasRelatedWork W2599763536 @default.
- W4308385304 hasRelatedWork W2900720404 @default.
- W4308385304 hasRelatedWork W2902679640 @default.
- W4308385304 hasRelatedWork W3004966710 @default.
- W4308385304 hasRelatedWork W3031381806 @default.
- W4308385304 hasRelatedWork W4224039515 @default.
- W4308385304 isParatext "false" @default.
- W4308385304 isRetracted "false" @default.
- W4308385304 workType "article" @default.